Claims for Patent: 8,168,593

Summary for Patent: 8,168,593

Title:	Mutated netrin-4, fragments thereof and their use as medicines
Abstract:	A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.
Inventor(s):	Plouet; Jean (Paris, FR), Alemany; Monica (Paris, FR)
Assignee:	Centre National de la Recherche Scientifique (Paris, FR) IVS Institut des Vaisseaux et du Sang (Paris, FR)
Application Number:	13/171,756
Patent Claims:	1. An isolated fragment of Netrin 4 protein consisting of the amino acid sequence SEQ ID NO: 12. 2. A pharmaceutical composition, comprising: a peptide consisting of the amino acid sequence SEQ ID NO: 12, as an active ingredient; and a pharmaceutically acceptable vehicle. 3. The pharmaceutical composition of claim 2, further comprising an agent selected from the group consisting of: bevacizumab, pegaptanib, ranibizumab, and any other anti-VEGF agent. 4. An isolated nucleic acid consisting of a nucleotide sequence coding for the peptide consisting of the amino acid sequence SEQ ID NO: 12. 5. The nucleic acid of claim 4 consisting of the nucleotide sequence SEQ ID NO: 11. 6. A recombinant vector comprising the nucleic acid of claim 5. 7. The recombinant vector of claim 6, selected from the group consisting of plasmid, cosmid, phage and virus DNA. 8. A host organism transformed by the recombinant vector of claim 6. 9. The host organism of claim 8, wherein the organism is a virus, bacteria, yeast, fungus, plant or mammalian cell. 10. A pharmaceutical composition, comprising as active ingredient at least one selected from the group consisting of: a nucleic acid consisting of the nucleotide sequence SEQ ID NO: 11; and a recombinant vector comprising a nucleic acid consisting of the nucleotide sequence SEQ ID NO: 11, and a pharmaceutically acceptable vehicle. 11. A pharmaceutical composition, comprising: a nucleic acid consisting of a nucleotide sequence coding for the peptide of SEQ ID NO: 12, as an active ingredient; and a pharmaceutically acceptable vehicle.

Details for Patent 8,168,593

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2024-11-22